Plasma phospho-tau217 for Alzheimer’s disease diagnosis in primary and secondary care using a fully automated platform
Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease
Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials
Machine learning prediction of tau‐PET in Alzheimer’s disease using plasma, MRI, and clinical data
Alpha-synuclein seed amplification assay longitudinal outcomes in Lewy body disease spectrum.
Altered Empathy Processing in Frontotemporal Dementia.
Diagnosis of Alzheimer’s disease using plasma biomarkers adjusted to clinical probability.
A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests.
Lewy body pathology exacerbates brain hypometabolism and cognitive decline in Alzheimer’s disease.
Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care
Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment
MRI Signature of α-Synuclein Pathology in Asymptomatic Stages and a Memory Clinic Population
Revised criteria for the diagnosis and staging of Alzheimer’s disease
Disease progression modelling reveals heterogeneity in trajectories of Lewy-type α-synuclein pathology
Tau Positron Emission Tomography for Predicting Dementia in Individuals With Mild Cognitive Impairment
Disease staging of Alzheimer’s disease using a CSF-based biomarker model
A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings
Highly Accurate Blood Test for Alzheimer’s Disease Comparable or Superior to Clinical CSF Tests.
Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies.
The α-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases.
DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease.
Cognitive effects of Lewy body pathology in clinically unimpaired individuals.
Clinical effects of Lewy body pathology in cognitively impaired individuals.
CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease.
🚨New paper alert! This study led by @SEMastenbroek aims to make detection of α-synuclein pathology in the brain more time- and cost-effective. Out now in Nature Communications! 🔗 Full article: https://www.nature.com/articles/s41467-025-62458-7.epdf?sharing_token=fJsM7nw6WLFQSLEmJtlXiNRgN0jAjWel9jnR3ZoTv0MDVkWnZxGsgtCMfY18v2PG-JBJvKhRsSwlFHbyWcVEhi_UdJDYtyqFZKb0-1LE-RJuxLzTxso4Wsn_ZLSgyRQKvtbjLPDfKEVHUrWMYnYD648e1kcTBiQcj_tBKohdF6g%3D
A thread🧵👇
6/🧵Taken together, we present an accurate two-step approach for predicting LBP in the brain using a smell test followed by CSF SAA testing in smell-test positive individuals. This could minimize costs, reduce patient burden, and improve the known underdiagnosis of DLB and PD.
A huge thanks to all authors and collaborators who made this work possible! @OskarHansson9 @LECollij @_JakeVogel_ @SebastianPalmqv @FBarkhof @RikOssenkoppele and all not on X.
🚨Publication alert: This study led by @WuestefeldAnika aims to provide a more granular understanding of how tau pathology leads to specific cognitive decline in Alzheimer's disease. 🧠 Out now in Alzheimer’s & Dementia! Read it here:
🧵👇
Tau, atrophy, and domain‐specific cognitive impairment in typical Alzheimer's disease
INTRODUCTION A granular understanding of the mechanisms linking tau pathology to cognitive decline in Alzheimer's diseas...
doi.org
7⃣This suggests that region-specific atrophy functions as one pathway of tau-induced cognitive subdomain impairments. Yet, large portions of variance remains unexplained, highlighting the need for investigating other mechanistic links.🔬
8⃣A huge thank you to all authors as well as the #ADNI study participants who made this work possible. Your contributions are vital for advancing our understanding of the disease and contribute to #ENDALZ.
6⃣Do certain regions uniquely mediate a given tau-cognition association? - Yes, tau–immediate recall was mediated by several MTL regions, tau–recognition by hippocampus & tau–semantic fluency by inferior temporal gyrus.
Last but not least! Stop by today and tomorrow for the final two talks of our group at #AAIC2025!
Third day of #AAIC2025! Today our team will present on fluid biomarkers in clinical practice. Come say hi!
Good morning! After a great first day of #AAIC2025 with an amazing welcoming reception, we hope to see you bright and early on the second day at our talks and posters!
Our group is kicking off the first day of #AAIC2025 with four oral presentations and six posters! Come find us!
Come check out our posters today at #AIC2025!
As FDA-approved Alzheimer’s treatments reach patients, validating the ALZpath p-Tau217 assay against gold standard neuropathological outcomes is key. Our new neuropathology cohort study led by @DivyaBali06 is now out in Acta Neuropathologica Comms! 🔗
Comparison of plasma ALZpath p-Tau217 with Lilly p-Tau217 and p-Tau181 in a neuropathological...
There is an urgent need for accurate and validated methods to measure plasma phosphorylated tau (p-Tau) biomarkers i...
actaneurocomms.biomedcentral.com
In conclusion, p-Tau217ALZpath exhibited similar performance to p-Tau181Lilly, but its correlations with AD pathology measures were significantly lower than p-Tau217Lilly. Future studies are needed to replicate these findings in larger cohorts.
Big thanks to all the co-authors for their invaluable contributions: @gesalbla, Thomas Beach, Geidy Serrano, Alireza Atri, Eric Reiman, Andreas Jeromin, @OskarHansson9, and Shorena Janelidze.
New manuscript alert! Are plasma biomarkers🩸 predictive of Alzheimer’s disease progression in Down Syndrome (DS)? Our new study in collaboration with the ABC-DS consortium has now been published in @lancetneurology:
Prediction of amyloid and tau brain deposition and cognitive decline in people with Down syndrome...
Baseline and longitudinal plasma p-tau217 were associated with subsequent decline in global cognition, progression to de...
www.thelancet.com
7⃣These findings support implementation of especially plasma p-tau217, and potentially also GFAP, in prognostic workup of AD in people with DS in both clinical practice and drug trials.
A huge thanks to the @abc_ds_ team, all co-authors, and the participants of the study.
🚨Exciting new preprint from a great collaboration between our group and the talented PhD student @jorittmo from @_JakeVogel_'s group! They investigate how the 🧠 reorganises in the context of age and AD. Dive into the details here 🧵👇
How does the brain reorganize in the context of age and AD?
Are functional changes in age and AD similar?
Are these changes dynamic across the age/AD spectrum?
We unpack these questions in a sample of N=973 with AD biomarkers
Preprint: http://tinyurl.com/ymv8s7h8
1/
⬇️🧵
So excited and honored to be invited to present the opening plenary at #AIC2025 this year in Toronto! 🧠
🙏 I would be very grateful if you could help me gather the most inspiring papers (including your own!) of the past year by completing this survey: https://alz.surveymonkey.com/r/923BTQK
Immunoassay choice for #pTau217 is important!
In this study, we show that LMW #pTau217 is more specific to Alzheimers pathology than HMW #pTau217 immunoassay designs – which can give false-positives.
@biofinder_study @OskarHansson9
A comparison of p‐tau assays for the specificity to detect tau changes in Alzheimer's disease
INTRODUCTION We evaluated differences in p-tau levels between Alzheimer's disease (AD), a condition with brain-specific ...
alz-journals.onlinelibrary.wiley.com
🚨New paper in Alzheimer's & Dementia! We investigate whether p-tau immuno-assays selectively quantifying low-molecular-weight (LMW) tau (CNS) are more specific for tau changes in AD vs ALS than assays not differentiating between LMW and high-MW (PNS) tau👇
A comparison of p‐tau assays for the specificity to detect tau changes in Alzheimer's disease
We evaluated differences in p‐tau levels between Alzheimer's disease (AD), a condition with brain‐specific changes i...
pmc.ncbi.nlm.nih.gov
6/🧵Concluding, plasma assays specific for LMW p-tau are preferable in the diagnostic workup of AD, with fewer false positive findings, especially in diverse population-based communities where peripheral neuropathy may produce high p-tau levels when using non-LMW specific assays.
A big thank you to all our collaborators from Bologna, Umeå, and Gothenburg and a special thanks to all co-authors @NicholasAshton @A_OrdunaDolado @DivyaBali06 @NiklasMattsson4 @OskarHansson9
and all not on X!
‼️New preprint!
We are happy to share our latest work led by @teanijarv investigating why tau pathology in Alzheimer’s disease (AD) often accumulates more in one hemisphere of the brain than the other.
Check out🔗 or dive into the details below👇
Hemispheric Asymmetry of Tau Pathology is Related to Asymmetric Amyloid Deposition in Alzheimer’s...
The distribution of tau pathology in Alzheimer’s disease (AD) shows remarkable inter-individual heterogeneity, including ...
www.biorxiv.org
6/🧵Our findings suggest that regional vulnerability to Aβ, not reduced inter-hemispheric connectivity, drives asymmetric tau accumulation in AD. This strengthens the link between Aβ and tau and supports the evidence of early anti-Aβ interventions to help limit tau buildup.
Big thanks to all co-authors and collaborators!
@RikOssenkoppele @ErikRubenSmith @LECollij @aitchbi @jorittmo @karlssonlinda1 @DaniellevWe @_JakeVogel_ @EStomrud @SebastianPalmqv @NiklasMattsson4 @NicolaSpotorno @OskarHansson9 + those not on X
🧠Exciting new findings from a great collaboration between the BioFINDER study and the talented @xiaoyucaly from @_JakeVogel_ group!! In their preprint, they show that tau presence and tau load are guided by unique brain mechanisms. Dive into the details here 👇
🧠New preprint alert! Tau, the pathological protein in AD, spreads through the brain in a very particular pattern. But what drives this pattern?
We found that WHERE tau pathology appears, and HOW MUCH accumulates there, are governed by different mechanisms. Check out our…